Biechele Royce Advisors’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
$17.8M Buy
197,754
+7,612
+4% +$640K 5.87% 5
2024
Q2
$15M Buy
190,142
+9,681
+5% +$794K 5.05% 6
2024
Q1
$15.7M Buy
180,461
+1,113
+0.6% +$95K 5.22% 7
2023
Q4
$14.8M Buy
179,348
+16,343
+10% +$1.25M 4.84% 7
2023
Q3
$12.8M Buy
163,005
+8,876
+6% +$743K 4.71% 9
2023
Q2
$13.6M Buy
154,129
+19,366
+14% +$1.67M 4.73% 7
2023
Q1
$10.9M Buy
134,763
+15,244
+13% +$1.24M 4.04% 11
2022
Q4
$9.29M Buy
+119,519
New +$9.69M 3.79% 12

Other funds holding MDT

Biechele Royce Advisors's MDT Position: Q3 2024 in Review

Biechele Royce Advisors increased its Medtronic (MDT) stake by 4% in Q3 2024, buying an estimated $640K and bringing the position to 197,754 shares worth $17.8M. The position accounts for 5.87% of the portfolio, ranked #5.

Biechele Royce Advisors first reported a position in MDT in Q4 2022 and has held it in 8 quarters since. 2,064 funds tracked by Wall St. Rank hold MDT as of Q3 2024.

  • Biechele Royce Advisors held 197,754 shares of Medtronic worth $17.8M as of Q3 2024.
  • Biechele Royce Advisors bought 7,612 Medtronic shares in Q3 2024, an estimated $640K.
  • Medtronic made up 5.87% of Biechele Royce Advisors's portfolio in Q3 2024, its #5 holding.
  • Biechele Royce Advisors first reported a position in Medtronic in Q4 2022 and has held it in 8 quarters since.
  • 2,064 funds tracked by Wall St. Rank held Medtronic as of Q3 2024.

Based on Biechele Royce Advisors's 13F filing for Q3 2024, filed 29 Oct 2024.